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Abstract We used Ro 46-8443, non-peptidic antagonist selec- 
tive of endothelin ETB receptors, to study the role of ET8 
receptors in rat hypertension models. In normotensive rats, Ro 
46-8443 decreased blood pressure, but in SHR and DOCA rats, 
it induced a pressor effect, due to blockade of ETs-mediated 
release of nitric oxide since L-NAME prevented it. In rats 
rendered hypertensive by chronic L-NAME, Ro 46-8443 did not 
induce a pressor but depressor effect. Thus, in DOCA rats and 
SHR, Ro 46-8443 reveals a predominant influence of endothelial 
'vasorelaxant' ETa receptors, while in normotensive rats the 
prevailing role of ETn receptors seems to be in mediating a 
vasoconstrictor tone. 
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1. Introduction 
The endothelin (ET) ETB receptor mediates complex 
cardiovascular effects. It is present on endothelial cells [1,2] 
where its activation induces endothelium-dependent relaxation 
via release of prostacyclin or nitric oxide or both, and may be 
present on smooth muscle cells to mediate direct vasoconstric- 
tion [3,4]. ETB receptors present in certain nerve fibers might 
also indirectly contribute to constriction [5]. 
In order to evaluate the role of ETA and ETB receptors in 
pathophysiological situations, we searched for low-molecular- 
weight antagonists either blocking all known receptors, or 
selective for one of these two receptors. We have already 
described Ro 46-2005 and bosentan (Ro 47-0203) as the first 
synthetic non-peptide mixed antagonists of ET receptors [6,7]. 
We are now describing [8] the first non-peptide ETB receptor 
selective antagonist, Ro 46-8443 ((S)-4-tert-butyl-N-[6-(2,3-di- 
hydroxypropyloxy)-5-(2-methoxyphenoxy)-2-(4-methoxyphe- 
nyl)pyrimidin-4-yl]benzenesulfonamide). Because of the non- 
peptidic nature and low molecular weight of these com- 
pounds, their kinetics and volume of distribution is compati- 
ble with a valuable evaluation of the role of the respective 
receptors. Here we report on the use of Ro 46-8443 to inves- 
tigate in vivo the function of ETB receptors in normotensive 
and hypertensive rats. In the first part of the study, we as- 
sessed the antagonistic properties of Ro 46-8443 on the in 
vivo effects of the ETB selective agonist sarafotoxin $6c. We 
then evaluated the hemodynamic effects of Ro 46-8443 in 
Wistar normotensive rats and in rats with different models 
of hypertension. 
2. Materials and methods 
2.1. Inhibition by Ro 46-8443 of ETB-mediated responses 
The inhibitory effect of Ro 46-8443 on the hemodynamic changes 
induced by the selective ETB agonist sarafotoxin $6c was studied in 
anesthetized normal rats. Male Wistar rats (350-390 g) were anesthe- 
tized with sodium thiobutabarbital (Inactin, 125 mg/kg i.p.). The fe- 
moral artery (for blood pressure monitoring) and vein (for injection) 
were cannulated. After stabilization of blood pressure, Ro 46-8443 (3 
or 10 mg/kg i.v,) or its vehicle (1 ml/kg of a 10% DMSO solution in 
water) was injected. 5 min later, increasing doses of sarafotoxin $6c 
were injected in a cumulative manner, each dose being given after 
stabilization of the effect of the previous dose on blood pressure. 
The hemodynamic changes induced by sarafotoxin $6c are composed 
of a depressor component (ETB-mediated endothelium-dependent r - 
laxation) and a pressor component (ETB-mediated smooth muscle cell 
contraction). The combined antagonism of receptors mediating oppo- 
site actions may lead to paradoxical observations, uch as absence of 
apparent inhibition or even potentiation of the effects of the agonist 
[9]. Because we had previously shown that blockade of nitric oxide 
synthase, which partially decreased the duration but not the amplitude 
of the blood pressure lowering effect of ET-I or sarafotoxin $6c, 
could unmask the inhibitory effect of antagonists on the pressor com- 
ponent [9], NC-nitro-L-arginine (L-NAME, 10 mg/kg i.v.) was injected 
10 min before Ro 46-8443. 
2.2. Effects of Ro 46-8443 in normotensive and hypertensive rats 
Wistar-Kyoto (WKY) rats, spontaneously h pertensive rats (SHR), 
rats made hypertensive by deoxycorticosterone (40 mg), unilateral 
nephrectomy and salt (1% in drinking water) (DOCA rats) and rats 
made hypertensive by 5-day administration of L-NAME (30 mg/kg 
per day) in drinking water (all 320-380 g) were anesthetized with 
Inactin. The femoral artery and vein were cannulated for blood pres- 
sure measurements and i.v. injections, respectively. After stabilization 
of blood pressure, cumulative doses of Ro 46-8443 or its vehicle (10% 
DMSO in water) were injected in a volume of 0.5 ml/kg, each dose 
being given after stabilization of the effect of the previous dose on 
blood pressure. 
2.3. Mechanism of increase in blood pressure by Ro 46-8443 in SHR 
SHR were anesthetized aspreviously described and femoral artery 
and vein cannulated. In a first set of experiments, L-NAME, 10 mg/kg 
i.v. or its vehicle (1 ml/kg water) was injected. After stabilization of 
blood pressure (5-10 min), Ro 46-8443, 10 mg/kg was administered. 
In another set of experiments, the selective ETA receptor antagonist 
BQ-123 (cyclo [D-Trp-D-Asp-Pro-D-Val-Leu]) (10 mg/kg i.v.) or its 
vehicle (1 ml/kg of a 1.5% sodium bicarbonate solution) was injected 
in place of L-NAME or water, 5 min before administration of Ro 46- 
8443. 
2.4. Statistical analysis 
Results are expressed as mean + S.E.M. Analysis of variance for 
univariate repeated measures was used to assess the effect of Ro 46- 
8443 on dose-response curves of sarafotoxin $6c and the effect of L- 
NAME on pressor esponse to Ro 46-8443. 
In all other experiments, paired or unpaired Student's t-test were 
used. A P level less than 0.05 was considered significant. 
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3 Results  
3 1. Inhibition of ETa-mediated responses 
Sarafotoxin $6c exhibited a biphasic effect on blood pres- 
s,Ire with a marked but transient decrease in blood pressure 
(~lepressor effect) followed by a more sustained and moderate 
i~tcrease (pressor effect). Ro 46-8443 (3 and 10 mg/kg) inhib- 
ited both the depressor and pressor effects of sarafotoxin $6c 
(Zig. 1). A dose of 10 mg/kg had a virtually complete inhibi- 
t )ry effect on both components. 
." 2. Effects of Ro 46-8443 in normotensive and hypertensive 
rats 
In anesthetized normotensive WKY rats (baseline mean ar- 
t ~'rial blood pressure 108 + 3 mmHg), Ro 46-8443 had no ef- 
t~ct on blood pressure at 3 and 10 mg/kg, while at 30 mg/kg it 
s~gnificantly decreased blood pressure by 22+4 mmHg 
( P < 0.05) (Fig. 2). In contrast, in SHR (baseline mean artery 
blood pressure 169 + 3 mmHg), Ro 46-8443 exhibited a dose- 
tlependent increase in blood pressure, significant at 10 mg/kg 
(P < 0.01) (Fig. 2). Such a pressor effect of Ro 46-8443 was 
~lso observed in Doca rats (baseline mean arterial pressure 
128+20 mmHg), where doses of Ro 46-8443 of 3 mg/kg 
and above induced significant increases in mean arterial blood 
pressure (Fig. 2). In marked contrast, rats chronically treated 
with L-NAME (mean arterial blood pressure 147 + 2 mmHg) 
responded to Ro 46-8443 by a decrease in blood pressure, 
significant at 30 mg/kg (Fig. 3). 
3.3. Mechanism of increase in blood pressure by Ro 46-8443 
in SHR 
Ro 46-8443 (10 mg/kg) induced a 10 mmHg increase in 
blood pressure in anesthetized SHR. Administration of L- 
NAME (10 mg/kg) --  which increased blood pressure by 
36 + 4 mmHg -- completely prevented this increase in blood 
pressure (Fig. 4). In contrast, BQ-123 (10 mg/kg) did not 
modify the pressor effect of Ro 46-8443 (Fig. 5). 
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Fig. 2. Effect of i.v. Ro 46-8443 or its vehicle on mean arterial 
blood pressure (MABP) in anesthetized Wistar-Kyoto rats, sponta- 
neously hypertensive rats (SHR) and DOCA hypertensive rats. 
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Fig. 3. Effect of i.v. Ro 46-8443 or its vehicle on blood pressure in 
anesthetized rats pretreated with L-NAME (30 mg/kg/day in drink- 
ing water for 5 days). 
4. Discussion 
The results of our study show that both in DOCA rats and 
in SHR, Ro 46-8443 exhibits a pressor effect which reveals a 
tonic influence of endothelial 'vasorelaxant' ETB receptors, 
while in normotensive rats (and in rats rendered hypertensive 
by injection of L-NAME) the prevailing role of ETB receptors 
seems to be in mediating a vasoconstrictor tone. 
We have shown in a separate manuscript [8] that Ro 46- 
8443 is a selective antagonist of the ETB receptor and inhibits 
in vitro various responses mediated by this receptor. No par- 
tial agonistic effect was detected. It is to our knowledge the 
first non-peptidic ETB receptor selective antagonist described. 
This non-peptidic nature and its selectivity make it a particu- 
larly suitable tool for evaluating in vivo the status of ETB 
receptors. 
The present study shows that in vivo (as in vitro), Ro 46- 
8443 behaves as an inhibitor of ETB-mediated responses. Ro 
46-8443 fully inhibited the depressor - -  endothelium-depen- 
dent - -  and pressor effects of sarafotoxin $6c. We used L- 
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NAME to prevent he nitric oxide pathway of the endothe- 
lium-dependent relaxation to sarafotoxin $6c, in order to bet- 
ter reveal the antagonistic effect of Ro 46-8443 on the pressor 
action of sarafotoxin $6c, as already described [9]. 
In two different rat models of hypertension, Ro 46-8443 
exhibited a dose-dependent pressor effect, while it did not 
show such an effect in normotensive rats or in rats made 
hypertensive by chronic blockade of nitric oxide synthase 
with L-NAME. The observations made in SHR and DOCA 
rats suggest that the pressor effect of Ro 46-8443 might be due 
to the inhibition by Ro 46-8443 of the ETB receptor-mediated 
release of endothelium-dependent r laxing factor(s), singularly 
nitric oxide. This hypothesis i  confirmed by the fact that L- 
NAME completely abolished the pressor effect of Ro 46-8443 
in SHR, showing that if Ro 46-8443 cannot inhibit the release 
of nitric oxide, it loses its pressor effect. Because nitric oxide 
plays a basal role in the modulation of blood pressure, its 
inhibition by Ro 46-8443 leads to an increase in blood pres- 
sure, either by direct inhibition of the release of nitric oxide or 
via potentiation of the effect of vasoconstrictor substances. 
Alternatively, another hypothesis was that the pressor effect 
of Ro 46-8443 in SHR could be due to an activation of ETA 
receptors by an increased level of plasma ET-1. Indeed, ET 
receptor antagonists have been shown to increase plasma ET- 
1 concentrations via antagonism of ETB receptors [10], and 
Ro 46-8443 itself has been shown to increase plasma ET-1 
levels (data not shown). The observation that BQ-123 had 
no effect on the increase in blood pressure by Ro 46-8443 
shows that ETA receptors are not involved. 
Overall, these findings suggest hat 'dilating' ETB receptors 
seem to actively modulate blood pressure in hypertension. 
This is in contrast with an apparent absence of basal dilating 
role of ETB receptors in the normotensive state, where dilat- 
ing ETB receptors eem to play no significant role in the 
regulation of blood pressure, since no pressor effect of Ro 
46-8443 was observed. This discrepancy may be due either 
to an increase of the basal level of endothelium-dependent 
vasodilation in situations of hypertension, as some [11] but 
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not others [12] have suggested, or to an up-regulation of en- 
dothelial 'vasodilating' ETB receptors. The latter hypothesis 
s apported by similar results found in a rat model of pulmon- 
ary hypertension [13]. 
However, up-regulation of 'constricting' ETB receptors has 
also been described in rat models of hypertension. Indeed, 
tonstricting ETB receptors are up-regulated in renal arteries 
t"om SHR, as shown by an increased responsiveness to sar- 
afotoxin S6c [14], and in SHR aorta, as shown by an in- 
t reased binding of an ETB selective ligand in aortic smooth 
] mscle cells from SHR [15]. A contribution of ETB receptors 
~ lediating constriction i the pathogenesis of high blood pres- 
sure in SHR is further suggested by the observation that 
laixed ETA and ETB receptor antagonism with bosentan pro- 
\ ided a larger decrease in blood pressure in SHR as compared 
~o selective ETA antagonism using BQ-123. Overall, the data 
: uggest hat not only constricting ETB receptors but also di- 
l~ting ETB receptors are up-regulated in hypertension, either 
', ia a common mechanism of regulation or by a compensatory 
Nacrease in the 'moderating' endothelial ETB receptors upon 
,n  increase in arterial pressure or shear stress. However, one 
, an question why the present experiments using Ro 46-8443 
do not reveal the contribution of the constricting receptors to 
i~lood pressure regulation in SHR but only the 'relaxing' ETB 
eceptors.The existence of a cross-talk between ETA and ETB 
~eceptors present on smooth muscle cells [16], allowing ETA 
~eceptors to compensate upon blockade of ETB receptors 
, rely, may provide an explanation for the lack of blood pres- 
ure  lowering effect of ETB receptor antagonists (present 
tudy, and [17]). 
In normotensive rats, Ro 46-8443 exhibited no effect on 
flood pressure at 3 and 10 mg/kg. This is in agreement with 
he described absence of substantial change in blood pressure 
n rats treated with BQ-788 (3 mg/kg), a peptidic selective ETB 
• eceptor antagonist [18]. In contrast, Ro 46-8443 exhibited a
dgnificant depressor effect at the higher dose of 30 mg/kg. 
l'his suggests a prevalent contribution of constricting ETB 
• eceptors in normotensive rats. The need for a higher dose 
)f Ro 46-8443 as compared to the doses leading to pressor 
effects in SHR and DOCA rats may be due to the need for Ro 
46-8443 to reach the smooth muscle cells for blocking con- 
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stricting ETB receptors and eliciting this depressor effect in 
normotensive rats. 
In conclusion, our data show that ETB receptor blockade 
with Ro 46-8443, which may lower blood pressure in normo- 
tensive rats, in contrast leads to an increase in blood pressure 
in spontaneously h pertensive and DOCA hypertensive rats, 
revealing an upregulation of relaxing ETB receptors in situa- 
tions of hypertension. We have previously shown that Ro 46- 
8443 was able to prevent neurogenic nflammation i the dura 
mater of the rat [19]. If this model can be used as a model of 
migraine, as suggested by Moskowitz [20], then Ro 46-8443 
and other ETB receptor antagonists could be potentially use- 
ful as anti-migraine agents. However, our findings from the 
present study suggest hat ETB receptor selective antagonists 
raise blood pressure in rat models of hypertension. If this 
finding applies to man, ETB receptor selective antagonists 
should be used with caution in patients with cardiovascular 
diseases. 
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